Once-weekly ALTUVIIIO® approved in Japan as a new class of factor VIII therapy for hemophilia A Post author: Post published:September 25, 2023 Post category:uncategorized The Japanese Ministry of Health, Labor, and Welfare (MHLW) has granted marketing authorization for ALTUVIIIO. You Might Also Like Impact of CLK kinase inhibitors 1C8 and GPS167 on cancer cell proliferation and metastasis May 20, 2024 Could vitamin D be the missing link in managing type 2 diabetes? Recent study weighs in October 29, 2024 New review suggests balanced biocide use for sustainability and health benefits August 9, 2024
Impact of CLK kinase inhibitors 1C8 and GPS167 on cancer cell proliferation and metastasis May 20, 2024
Could vitamin D be the missing link in managing type 2 diabetes? Recent study weighs in October 29, 2024